bgb-a445
Showing 1 - 4 of 4
NSCLC Trial (BGB-A445, Docetaxel, Tislelizumab)
Not yet recruiting
- Non-Small Cell Lung Cancer
- BGB-A445
- +6 more
- (no location specified)
Sep 6, 2023
Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma Trial (BGB-A445, Tislelizumab)
Not yet recruiting
- Urothelial Carcinoma
- +2 more
- BGB-A445
- Tislelizumab
- (no location specified)
Dec 15, 2022
Advanced Solid Tumor Trial in Australia, New Zealand, United States (BGB-A445, tislelizumab)
Recruiting
- Phase 1a:Advanced Solid Tumors; Phase 1b: Non-small Cell Lung Cancer (NSCLC) and Head and Neck Squamous Cell Carcinoma (HNSCC)
- BGB-A445
- tislelizumab
-
Pittsburgh, Pennsylvania
- +11 more
Aug 25, 2022
NSCLC, Metastatic NSCLC Trial (Tislelizumab, BGB-A445, LBL-007)
Not yet recruiting
- Non-small Cell Lung Cancer
- Metastatic Non-small Cell Lung Cancer
- Tislelizumab
- +7 more
- (no location specified)
Dec 14, 2022